Cargando…

Anakinra Pilot – a clinical trial to demonstrate safety, feasibility and pharmacokinetics of interleukin 1 receptor antagonist in preterm infants

BACKGROUND: Bronchopulmonary dysplasia (BPD), its complication pulmonary hypertension (BPD-PH) and preterm brain and gut injury lead to significant morbidity and mortality in infants born extremely prematurely. There is extensive evidence that the pro-inflammatory cytokine interleukin 1 (IL-1) plays...

Descripción completa

Detalles Bibliográficos
Autores principales:	Green, Elys A., Metz, David, Galinsky, Robert, Atkinson, Rebecka, Skuza, Elizbeth M., Clark, Megan, Gunn, Alistair J, Kirkpatrick, Carl M., Hunt, Rod W., Berger, Philip J., Nold-Petry, Claudia A., Nold, Marcel F.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2022
Materias:	Immunology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9647081/ https://www.ncbi.nlm.nih.gov/pubmed/36389766 http://dx.doi.org/10.3389/fimmu.2022.1022104

Ejemplares similares

Interleukin-1: an important target for perinatal neuroprotection?
por: Kelly, Sharmony B., et al.
Publicado: (2022)

The Role of the Interleukin-1 Family in Complications of Prematurity
por: Green, Elys A., et al.
Publicado: (2023)

Timing of the First Dose of the Hepatitis B Vaccine in Preterm Infants
por: Lei, Donna, et al.
Publicado: (2022)

Interleukin-1 blockade attenuates white matter inflammation and oligodendrocyte loss after progressive systemic lipopolysaccharide exposure in near-term fetal sheep
por: Kelly, Sharmony B., et al.
Publicado: (2021)

A systematic review of immune-based interventions for perinatal neuroprotection: closing the gap between animal studies and human trials
por: Kelly, Sharmony B., et al.
Publicado: (2023)

Interleukin 37 is a fundamental inhibitor of innate immunity
por: Nold, Marcel F, et al.
Publicado: (2010)

Circulating Interleukin-37 Levels in Healthy Adult Humans – Establishing a Reference Range
por: Santarelli, Danielle M., et al.
Publicado: (2021)

Failure of Interferon γ to Induce the Anti-Inflammatory Interleukin 18 Binding Protein in Familial Hemophagocytosis
por: Nold-Petry, Claudia A., et al.
Publicado: (2010)

The role of interleukin-1 in perinatal inflammation and its impact on transitional circulation
por: Owen, Josephine C., et al.
Publicado: (2023)

Interleukin-1 Receptor Antagonist Protects Newborn Mice Against Pulmonary Hypertension
por: Bui, Christine B., et al.
Publicado: (2019)

The Effect of In Utero Exposure to Maternal Inflammatory Bowel Disease and Immunomodulators on Infant Immune System Development and Function
por: Prentice, Ralley E., et al.
Publicado: (2023)

Gp96 Peptide Antagonist gp96-II Confers Therapeutic Effects in Murine Intestinal Inflammation
por: Nold-Petry, Claudia A., et al.
Publicado: (2017)

Protein C preserves microcirculation in a model of neonatal septic shock
por: Fischer, Doris, et al.
Publicado: (2009)

The immunological landscape in necrotising enterocolitis
por: Cho, Steven X., et al.
Publicado: (2016)

Interleukin-1 Antagonist Anakinra in Amyotrophic Lateral Sclerosis—A Pilot Study
por: Maier, André, et al.
Publicado: (2015)

The interleukin-1 receptor antagonist anakinra improves endothelial dysfunction in streptozotocin-induced diabetic rats
por: Vallejo, Susana, et al.
Publicado: (2014)

Interleukin-1 receptor antagonist anakinra in association with remdesivir in severe COVID-19: A case report
por: Franzetti, Marco, et al.
Publicado: (2020)

Remifentanil ameliorates intestinal ischemia-reperfusion injury
por: Cho, Steven SC, et al.
Publicado: (2013)

Refining anti‐inflammatory therapy strategies for bronchopulmonary dysplasia
por: Rudloff, Ina, et al.
Publicado: (2016)

Untersuchung der Reaktion $e^{+}e^{-} \to \mu^{+}\mu^{-}$-beim OPAL Experiment
por: Nold, F
Publicado: (1992)

Ocular modifications in a young girl with cryopyrin-associated periodic syndromes responding to interleukin-1 receptor antagonist anakinra
por: Terrada, Celine, et al.
Publicado: (2011)

The Safety and Efficacy of Anakinra, an Interleukin-1 Antagonist in Severe Cases of COVID-19: A Systematic Review and Meta-Analysis
por: Somagutta, Manoj Kumar Reddy, et al.
Publicado: (2021)

Towards a Treatment for Neuroinflammation in Epilepsy: Interleukin-1 Receptor Antagonist, Anakinra, as a Potential Treatment in Intractable Epilepsy
por: Yamanaka, Gaku, et al.
Publicado: (2021)

The Anti-Atherosclerosis Effect of Anakinra, a Recombinant Human Interleukin-1 Receptor Antagonist, in Apolipoprotein E Knockout Mice
por: Ku, Eu Jeong, et al.
Publicado: (2022)

Persistent Inflammation in Cerebral Palsy: Pathogenic Mediator or Comorbidity? A Scoping Review
por: Paton, Madison C. B., et al.
Publicado: (2022)

Recurrent poliserositis succesfully treated with IL-1 receptor antagonist Anakinra
por: Lovillo, MS Camacho, et al.
Publicado: (2011)

Peri- and Postoperative Treatment with the Interleukin-1 Receptor Antagonist Anakinra Is Safe in Patients Undergoing Renal Transplantation: Case Series and Review of the Literature
por: Mulders-Manders, Catharina M., et al.
Publicado: (2017)

Parsing the IL-37-Mediated Suppression of Inflammasome Function
por: Rudloff, Ina, et al.
Publicado: (2020)

Anti-Inflammatory Therapies for Treatment of Inflammation-Related Preterm Brain Injury
por: Prasad, Jaya D., et al.
Publicado: (2021)

PReS-FINAL-2333: Long term efficacy of interleukin-1 receptor antagonist (anakinra) in a multicentric cohort of patients affected by idiopathic recurrent pericarditis
por: Finetti, M, et al.
Publicado: (2013)

Successful treatment of cytomegalovirus associated hemophagocytic lymphohistiocytosis with the interleukin 1 inhibitor – anakinra
por: Divithotawela, Chandima, et al.
Publicado: (2015)

The IL-1 Antagonist Anakinra Attenuates Glioblastoma Aggressiveness by Dampening Tumor-Associated Inflammation
por: Hübner, Max, et al.
Publicado: (2020)

Modulation of working memory duration by synaptic and astrocytic mechanisms
por: Becker, Sophia, et al.
Publicado: (2022)

Rational design of antisense oligonucleotides modulating the activity of TLR7/8 agonists
por: Alharbi, Arwaf S, et al.
Publicado: (2020)

Anakinra, an interleukin-1 receptor antagonist, increases the morphine analgesic effect and decreases morphine tolerance development by modulating oxidative stress and endoplasmic reticulum stress in rats
por: AVCI, Onur, et al.
Publicado: (2020)

Lipopolysaccharide-induced changes in the neurovascular unit in the preterm fetal sheep brain
por: Disdier, Clémence, et al.
Publicado: (2020)

The Use of IL-1 Receptor Antagonist (Anakinra) in Idiopathic Recurrent Pericarditis: A Narrative Review
por: Baskar, Shankar, et al.
Publicado: (2016)

Anakinra and related drugs targeting interleukin-1 in the treatment of cryopyrin-associated periodic syndromes
por: Bachove, Inessa, et al.
Publicado: (2014)

Post-infection immunocomplex glomerulonephritis and Legionnaires' disease in a patient with adult Still's disease during treatment with interleukin 1 receptor antagonist anakinra: a case report
por: Scholtze, Dieter, et al.
Publicado: (2011)

A multicentre, randomised, double-blind, placebo-controlled trial with the interleukin-1 receptor antagonist anakinra in patients with systemic-onset juvenile idiopathic arthritis (ANAJIS trial)
por: Quartier, Pierre, et al.
Publicado: (2010)

Cannot write session to /tmp/vufind_sessions/sess_jdecose48v9ibbkd8lbj8t5ogk